Two Sigma Securities’s Gain Therapeutics GANX Stock Holding History
Bought
Maintained
Sold
Other funds holding GANX
PCM
GCP
DCM
Two Sigma Securities's GANX Position: Q2 2026 in Review
Two Sigma Securities opened a new position in Gain Therapeutics (GANX) in Q2 2026: 12,739 shares worth $25.9K. The stake represents ﹤0.01% of the portfolio and ranks #1459 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in GANX as recently as Q3 2025.
Two Sigma Securities first reported a position in GANX in Q4 2022 and has held it in 4 quarters since. The position peaked at $48.4K in Q3 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.
- Two Sigma Securities held 12,739 shares of Gain Therapeutics worth $25.9K as of Q2 2026.
- Gain Therapeutics was a new Two Sigma Securities position in Q2 2026.
- Gain Therapeutics made up ﹤0.01% of Two Sigma Securities's portfolio in Q2 2026, its #1459 holding.
- Two Sigma Securities first reported a position in Gain Therapeutics in Q4 2022 and has held it in 4 quarters since.
- Two Sigma Securities's Gain Therapeutics position peaked at $48.4K in Q3 2025.
- 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.
Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.